Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CBMG Cellular Biomedicine Group (CBMG) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Cellular Biomedicine Group Stock (NASDAQ:CBMG) 30 days 90 days 365 days Advanced Chart Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get CBMG alerts:Sign Up Key Stats Today's Range N/A50-Day Range$17.67▼$19.7552-Week Range N/AVolume8,375 shsAverage Volume129,776 shsMarket Capitalization$384.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.Read More… 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Receive CBMG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellular Biomedicine Group and its competitors with MarketBeat's FREE daily newsletter. Email Address CBMG Stock News HeadlinesUS Cellular to Sell Certain Spectrum Licenses to AT&T For $1.02 BillionNovember 8, 2024 | msn.comUS Cellular agrees to sell $1 billion in assets to rival carrierNovember 8, 2024 | bizjournals.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 21, 2024 | WealthPress (Ad)Intra-Cellular bolsters Caplyta data with another Phase III winNovember 6, 2024 | finance.yahoo.comIntra-Cellular price target raised to $89 from $81 at JPMorganNovember 5, 2024 | markets.businessinsider.comIntra-Cellular announces results from Study 304 on lumateperoneNovember 5, 2024 | markets.businessinsider.comConsumer Cellular Announces New Barbie™ Flip PhoneNovember 1, 2024 | tmcnet.comIntra-Cellular price target raised to $135 from $130 at Cantor FitzgeraldNovember 1, 2024 | msn.comSee More Headlines CBMG Stock Analysis - Frequently Asked Questions How were Cellular Biomedicine Group's earnings last quarter? Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) issued its earnings results on Monday, November, 9th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.25. The biotechnology company had revenue of $0.03 million for the quarter. What other stocks do shareholders of Cellular Biomedicine Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellular Biomedicine Group investors own include CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), Aduro Biotech (ADRO), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Bristol-Myers Squibb (BMY) and Intellia Therapeutics (NTLA). Company Calendar Last Earnings11/09/2020Today11/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CBMG CUSIPN/A CIK1378624 Webwww.cellbiomedgroup.com Phone347-905-5663FaxN/AEmployees217Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-144.80% Return on Assets-61.68% Debt Debt-to-Equity RatioN/A Current Ratio0.47 Quick Ratio0.47 Sales & Book Value Annual Sales$340,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / BookN/AMiscellaneous Outstanding Shares19,478,000Free FloatN/AMarket Cap$384.69 million OptionableOptionable Beta1.35 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CBMG) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellular Biomedicine Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellular Biomedicine Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.